A precision medicine approach to therapeutic resistance using KEAP1 somatic mutations

A precision medicine approach to therapeutic resistance using KEAP1 somatic mutations

Publication date: Jul 10, 2019

Dr Gerald Batist speaks to ecancer at the WIN 2019 Symposium in Paris about a precision medicine approach to therapeutic resistance using KEAP1 somatic mutations to target patients to correct protein-protein interaction disrupted by this mutation.

He explains that often cancer patients will relapse and second and third lines of therapy become unsuccessful due to resistance.

Dr Batist explains that using molecular modelling they have found a drug that can lower resistance and sensitise tumours to chemotherapies and immunotherapies.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.

ecancer.org/account/register.php

Concepts Keywords
Battery Tthe tumor
Canada Resistant metastatic disease
Chemotherapies Lung cancers
Chemotherapy Tumor tumor
Drug Design Tumor
Immunotherapies Immunotherapy
Immunotherapy Chemotherapies
Lung Immunotherapies
Metastatic Chemotherapy
Molecular Modeling Medicine
Molecular Modelling Clinical medicine
Mutation Cancer
Paradigm Carcinogenesis
Paris Oncology
Protein Drug resistance
Register Immunology
Relapse Psychopharmacology
Somatic Targeted therapy
Targeted Therapies Personalized onco-genomics
Toxicity Antineoplastic resistance
Transcription Factor Drug design
Tumor Chemotherapy
Molecular modeling
Php

Semantics

Type Source Name
gene UNIPROT KEAP1
gene UNIPROT ZNF746
disease MESH cancer
disease DOID cancer
disease MESH relapse
gene UNIPROT SOX3
gene UNIPROT PHPT1
gene UNIPROT ASAH1

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *